Henry Ooi
Cardiovascular Disease · Nashville, TNNPI 1942268693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Surgical Specialties Corporation (US), Inc. (dba Corza Medical) at 44.9% of the total. That places this record below the midpoint for cardiovascular disease clinicians in TN, where the typical reported total is $1,892.
Across 4 payments — averaging $84.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$151
- AstraZeneca$132
- Abbott$53
Across 36 payments — averaging $11,027 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$193K
- AstraZeneca$116K
- Amgen$61K
- Merck$22K
- Sanofi US Services Inc.$5K
What the payments were for
- Food & beverage$337100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $151 |
| AstraZeneca | 2 | $132 |
| Abbott | 1 | $53 |
How this compares
$337 in reported general payments places this provider in the 25th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 34 | $55,377 |
| JardianceEmpagliflozin | 31 | $51,012 |
| EliquisApixaban | 29 | $36,779 |
| Eplerenone | 14 | $1,289 |
| Potassium Chloride | 17 | $1,063 |
| Spironolactone | 52 | $545 |
| Metoprolol Succinate | 25 | $378 |
| Carvedilol | 37 | $247 |
| Losartan Potassium | 28 | $222 |
| Furosemide | 38 | $213 |
| Atorvastatin Calcium | 19 | $159 |
| Amlodipine Besylate | 22 | $133 |
| Rosuvastatin Calcium | 11 | $123 |
| Hydralazine Hcl | 12 | $60 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.